Predictive Technology Group, Inc. · OTC:PREDQ
Predictive Technology — LD Micro Invitational 2018
26 slides from Predictive Technology's conference presentation, Jun 4, 2018
Slide 1: LD Micro Invitational
LD Micro Invitational June 4, 2018 OTC: PRED predtechgroup.com
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking
Slide 3: Company Overview – Operates Three Subsidiaries
Company Overview – Operates Three Subsidiaries • Develops and • Develop and commercialize • Secure procurement of tissue commercializes novel regenerative human tissue, for Predictive Biotech products genetic-based diagnostics human cell and cellular and therapeutics products • Biorepository of DNA,
Slide 4: Investment Highlights
Investment Highlights • Pressing need for improved endometriosis diagnostics and therapeutics • Affects an estimated 1 in 10 women during their reproductive years (i.e., 15 to 49) which is approximately 176 million women in the world • Chronic and painfully debilitating disease from puberty to menop
Slide 5: Endometriosis is one of the most common health concerns for women
“Endometriosis is one of the most common health concerns for women, but it is poorly understood by both the public and by medical professionals. We need to increase awareness to bring more timely diagnoses to our patients and we need increased research funding to develop better remedies for endometr
Slide 6: About Endometriosis
About Endometriosis • Affects 1 in 10 women during their reproductive years* • 30-50% of women with endometriosis may experience fertility issues** • One of the leading causes of female infertility** • No therapeutic cure and most treatments are not suitable for long-term use due to side effects • S
Slide 7: What is Endometriosis?
What is Endometriosis? Endometriosis is an often painful disorder in which tissue that normally lines the inside of the uterus — the endometrium — grows outside the uterus. Endometriosis most commonly involves ovaries, fallopian tubes and tissue lining the pelvis. Rarely, endometrial tissue may spre
Slide 8: Endometriosis is Difficult to Diagnose
Endometriosis is Difficult to Diagnose • Patient history and physical exam are not reliable indicators • 9-11 years average time to diagnose, with an average of 5 different physician referrals • Shortcomings with invasive laparoscopy • Half of 250,000-300,000 U.S. endometriosis-related laparoscopic
Slide 9: Suite of Endometriosis and Infertility Tests
Suite of Endometriosis and Infertility Tests Diagnostic Test ARTGuide® Non-invasive diagnostic test for endometriosis and other genetic causes of infertility. Indicated for the 1 in 8 women with infertility leads to better decision making regarding IVF and other treatments Fertility Dx® ARTGuide® pl
Slide 10: Problem #1: Endometriosis Underlying Infertility
Problem #1: Endometriosis Underlying Infertility • 25-50% of infertile women have endometriosis* • IVF complications are greater in women with active endometriosis • Increased risk of adverse pregnancy outcomes in women with endometriosis • Evidence-based diagnosis for endometriosis was accompanied
Slide 11: Solution: ARTGuide®
Solution: ARTGuide® Diagnosis leads to better informed IVF decisions Low-risk Patients High-risk Patients • Increased IVF success and decreased • Better patient counseling regarding risks of complications IVF, pregnancy and endometriosis • Test may give patient greater confidence • Improved expectat
Slide 12: Fertility Dx®
Fertility Dx® The Problem Fertility DX® • Genetic conditions frequently cause • Specialized laboratory and counseling service infertility, every potential parent is a focused on delivering personalized and carrier for 2 to 8 rare recessive genetic comprehensive genetic diagnostic services to disease
Slide 13: ARTGuide® & Fertility Dx® Commercialization
ARTGuide® & Fertility Dx® Commercialization First Products to Market • Efficient sales to large yet highly concentrated market • 480 assisted reproduction technology (ART) clinics in the U.S.; 80% of market in 6 metro regions • Self-pay test with no reliance on reimbursement • 8-10 sales representat
Slide 14: Problem #2: Endometriosis and Chronic Pain
Problem #2: Endometriosis and Chronic Pain • Abnormal tumors cause ”To be honest, ENDO bleeding, scarring and ruins my life…it robs inflammation me of days each • Endometriosis can cause month…I am at my wits end with this chronic, debilitating pelvic disease. It always pain wins and I am • No relia
Slide 15: Solution: ENDORisk® and NHP-07 Therapeutic
Solution: ENDORisk® and NHP-07 Therapeutic Diagnostic - ENDORisk® Therapeutic – NHP-07 • Predictive genetic test for • Proprietary therapeutic for endometriosis covered by key endometriosis prevention and/or issued and pending patents suppression • Incorporates proprietary • Can be administered prio
Slide 16: Competitive Landscape
Competitive Landscape • No active competitors for predictive DNA endometriosis test • Small company has developed CNV markers • Immunologic, protein, gene expression, miRNA test, endometrial biopsy, CT scan tests under development • Growing pharma interest in endometriosis • AbbVie reported success
Slide 17: Product Pipeline in Spine Disorders
Product Pipeline in Spine Disorders • Current diagnostic methods are invasive and expensive • Need for diagnostic to determine course of care for better outcomes • Need for payers to better determine the risk of the insured population • Scoliosis Diagnostic Test • Proprietary genetic-based test pred
Slide 18: Assets from Development Collaborations
Assets from Development Collaborations • Library of 600,000 DNA samples with genetic birth defect or serious maternity issue • HIPAA compliant • Collected from most genetically diverse population in the U.S. • Believed to be the world’s largest DNA library related to women’s health • Corresponding p
Slide 19: Advanced regenerative medicine products
Advanced regenerative medicine products that enhance the body’s natural ability to heal and augment current therapies
Slide 20: Overview
Overview Predictive Biotech was established to: • Provide advanced regenerative medicine products • Enhance the body’s natural ability to heal • Augment current therapies What is Regenerative Medicine? • Regenerative medicine is an area of healthcare that has the potential to have a disruptive affec
Slide 21: How does Regenerative Medicine Work?
How does Regenerative Medicine Work? As our Bodies age we experience: Building Blocks: • Longer healing times • Increase inflammation • Over time, healthy tissue can become dysfunctional due to age and injury. A • Changing chemical environment human cell and tissue product (HCT/P) is • Cell exhausti
Slide 22: Product Portfolio
Product Portfolio CoreCyte”™ Cord Tissue Allograft Suspension CoreCyte™ is a minimally manipulated human tissue allograft suspension derived from the Wharton's Jelly of the umbilical cord. CoreCyte™ is processed to preserve the biological and structural integrity of Wharton's jelly for homologous us
Slide 23: Procurement and Process
Procurement and Process MOTHER > BIRTH > COLLECTION > CLEAN > PROCESSING > + Donors (mother and + All donated tissues are + Donated tissues are + Tissue is sanitized and * Each tissue is recorded father) are screened procured and collected collected and shipped cleaned prior to and separated into fo
Slide 24: Strong Revenue Growth - Cell and Tissue Products
Strong Revenue Growth - Cell and Tissue Products $4.5 $4.2M $4.0 t h • Achieved $15 million revenue o w G r run rate guidance at year end $3.5 e d $3.2M 2017 t inu $3.0 n g Co • Continued quarter-over-quarter $2.5 o n $2.2M t r growth $2.0 S $1.9M $1.5 • August 2017 achieved $10 $1.0 million revenue
Slide 25: Financial Highlights
Financial Highlights March 31, 2018 June 30, 2017 Cash $422,464 $968,202 Net Equity $42,819,393 $42,097,499 Current Ratio 1.72 1.38 Equity Turnover TTM .265 .057 No long-term operating liabilities No short- or long-term debt 24
Slide 26: In Summary
In Summary • Large, underserved market for endometriosis with need for improved diagnostics and therapeutics • Launch of 2 novel genetic-based endometriosis and fertility diagnostic/prognostic tests planned for 2018 • Novel endometriosis therapeutic with ability to treat and suppress/delay disease p
Predictive Technology Group — LD Micro Invitational 2018 on 6ix